Search

Ipsen SA.

Atvērts

SektorsFinanšu

165.5 2.1

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

160.1

Max

162.5

Galvenie mērījumi

By Trading Economics

Ienākumi

294M

403M

Pārdošana

334M

2.2B

P/E

Sektora vidējais

26.133

22.368

Dividenžu ienesīgums

1.03

Peļņas marža

18.405

Darbinieki

5,535

EBITDA

556M

1B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+8.63% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

1.03%

4.40%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

224M

13B

Iepriekšējā atvēršanas cena

163.4

Iepriekšējā slēgšanas cena

165.5

Ziņu noskaņojums

By Acuity

7%

93%

8 / 436 Rangs Finance

Ipsen SA. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. aug. 23:46 UTC

News

PG&E Corp shares are lower in after-market hours despite announcing an expansion of its Vehicle to Everything program and analysts' fair value estimate of $22.59.

2026. g. 24. aug. 23:46 UTC

News

DA Davidson initiated coverage of Vulcan Materials Co with a Buy rating. Shares traded higher in after-market hours following Monday's close of $276.04.

2026. g. 24. aug. 23:46 UTC

News

Jack Henry & Associates appoints Richard N. Preece to its Board of Directors, effective August 20, 2026. Shares are higher in after-market trading.

2026. g. 24. aug. 23:46 UTC

News

Parker-Hannifin Corp filed a mixed securities shelf to raise capital. Shares advanced in after-market trading, continuing a trend of higher daily closes.

2026. g. 24. aug. 23:31 UTC

News
Social Media

Kura Oncology shares are higher in after-market hours following CEO Troy Wilson's $1.2 million stock purchase, boosting his ownership to 1.214 million shares.

2026. g. 24. aug. 23:26 UTC

News

National Beverage Corp's shares are lower in after-market hours, despite recent strength and five consecutive higher closes, amid geopolitical concerns affecting market sentiment.

2026. g. 24. aug. 23:21 UTC

News

USD/HKD is trading lower, impacted by a stronger U.S. Dollar and economic pressures from new sanctions on Iran. Limited fluctuations persist in the market.

2026. g. 24. aug. 23:16 UTC

News

Trade Desk Inc's stock fell in after-hours trading following a prospectus filing for a mixed shelf offering of various securities. The company holds $1.12 billion in cash.

2026. g. 24. aug. 23:16 UTC

News

Coinbase Global Inc shares declined in after-market trading following the company's integration of Chainlink for real-time pricing of tokenized stocks on Base.

2026. g. 24. aug. 23:16 UTC

News

Diamondback Energy shares are lower in after-market hours amid concerns from CEO Van't Hof's recent insider selling of 10,000 shares at $214.66 each.

2026. g. 24. aug. 23:11 UTC

News

Nasdaq Inc shares are trading lower in after-market hours, reflecting broader market declines driven by weakness in technology stocks and geopolitical tensions.

2026. g. 24. aug. 23:11 UTC

News

Copart Inc shares are lower in after-market hours, reflecting unusual volatility amid broader market concerns over geopolitical tensions and economic disruptions.

2026. g. 24. aug. 23:06 UTC

Event
News

Gilead Sciences gains after European approval for Trodelvy and raises 2026 sales guidance to $30.1–$30.4 billion, reflecting strong performance in HIV and oncology.

2026. g. 24. aug. 23:01 UTC

Social Media
News

Re/Max Holdings Inc. announced a $450 million share repurchase authorization, contributing to a higher trading performance during after-market hours.

2026. g. 24. aug. 23:01 UTC

News

Grand Canyon Education shares declined in after-market hours following CFO Daniel E. Bachus's placement on paid administrative leave amid an ongoing investigation.

2026. g. 24. aug. 23:01 UTC

News

Herc Holdings shares rise in after-market trading following director Erik Olsson's $503K purchase of 3.1K shares, signaling potential confidence in the company.

2026. g. 24. aug. 23:01 UTC

News

Tyson Foods announced a $1 million commitment to the Harvest to Hallways initiative, enhancing childhood nutrition and food access, contributing to positive sentiment.

2026. g. 24. aug. 23:01 UTC

News

Oshkosh shares are higher in after-market trading following praise from Secretary of War Pete Hegseth for the company's defense manufacturing capabilities and tactical vehicles.

2026. g. 24. aug. 23:01 UTC

News

Vistra Corp shares rose in after-market trading after CEO James Burke bought 2,000 shares for $270,000, increasing his total ownership to 1.235 million shares.

2026. g. 24. aug. 22:51 UTC

News
Social Media

Boeing Co received a $131.23 billion contract for the F-15 Eagle Crest, with shares trading higher in after-market hours following the announcement.

2026. g. 24. aug. 22:16 UTC

News

A federal court upheld an $83.4 million award against Guardant Health for patent infringement, though shares are trading higher in after-market hours.

2026. g. 24. aug. 22:16 UTC

News

Kenneth S. Courtis bought $3.2 million in Alpha Metallurgical Resources shares, contributing to modest after-market gains following recent insider purchases.

2026. g. 24. aug. 22:06 UTC

News

Peabody Energy shares are lower in after-market hours following a class action lawsuit alleging misleading statements about its Centurion mine operations.

2026. g. 24. aug. 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

2026. g. 24. aug. 21:41 UTC

News

Franklin Resources announces cash distributions for ETFs, with payments set for September 2026. Shares are trading higher in after-market hours following the news.

2026. g. 24. aug. 21:02 UTC

News

DA Davidson initiated coverage of Advanced Drainage Systems with a Buy rating. Shares rose in after-market trading, closing at $143.73.

2026. g. 24. aug. 21:01 UTC

News

Owens Corning shares rise in after-market trading following a Buy rating from DA Davidson analyst Garik Shmois. The stock closed at $148.06.

2026. g. 24. aug. 20:07 UTC

Social Media
News

Uber Technologies has partnered with Zoomcar to offer intercity ride options in India. Shares are higher as the initiative launches in major cities.

2026. g. 24. aug. 20:07 UTC

News
Correlated Moves
Social Media

NVIDIA Corp's stock is lower amid negative sentiment from a senior manager's indictment for alleged AI chip smuggling and rising costs for customers.

2026. g. 24. aug. 20:07 UTC

News

Impinj Inc shares are lower amid pressure in the Semiconductors sector and concerns over licensing revenue from NXP. Adjusted EBITDA margin is 15%.

Salīdzinājums

Cenas izmaiņa

Ipsen SA. Prognoze

Cenas mērķis

By TipRanks

8.63% augšup

Prognoze 12 mēnešiem

Vidējais 177.5 EUR  8.63%

Augstākais 235 EUR

Zemākais 135 EUR

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ipsen SA. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

5 ratings

1

Pirkt

3

Turēt

1

Pārdot

Noskaņojums

By Acuity

8 / 436 Rangs Finanšu

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat